Cellular fibronectin promotes deep vein thrombosis in diet-induced obese mice.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
03 2021
Historique:
received: 22 09 2020
revised: 02 11 2020
accepted: 04 12 2020
pubmed: 11 12 2020
medline: 15 5 2021
entrez: 10 12 2020
Statut: ppublish

Résumé

Overweight and obesity are significant risk factors for deep vein thrombosis (DVT). Cellular fibronectin containing extra domain A (Fn-EDA), an endogenous ligand for toll-like-receptor 4 (TLR4), contributes to thrombo-inflammation. The role of Fn-EDA in the modulation of DVT is not elucidated yet. To determine whether Fn-EDA promotes DVT in the context of diet-induced obesity. Wild-type (WT) and Fn-EDA-deficient mice were either fed control or high-fat (HF) diet for 12 weeks. DVT was induced by inferior vena cava (IVC) stenosis and evaluated after 48 hours. Cellular Fn-EDA levels in the plasma of venous thromboembolism (VTE) patients were measured by sandwich ELISA. We found that cellular Fn-EDA levels were significantly elevated in VTE patients' plasma and positively correlated with body mass index. HF diet-fed WT mice exhibited increased DVT susceptibility compared with control diet-fed WT mice. In contrast, HF diet-fed Fn-EDA-deficient mice exhibited significantly reduced thrombus weight and decreased incidence (%) of DVT compared with HF diet-fed WT mice concomitant with reduced neutrophil content and citrullinated histone H3-positive cells (a marker of NETosis) in IVC thrombus. Exogenous cellular Fn-EDA potentiated NETosis in neutrophils stimulated with thrombin-activated platelets via TLR4. Genetic deletion of TLR4 in Fn-EDA These results demonstrate a previously unknown role of Fn-EDA in the DVT exacerbation, which may be an essential mechanism promoting DVT in the setting of diet-induced obesity.

Sections du résumé

BACKGROUND
Overweight and obesity are significant risk factors for deep vein thrombosis (DVT). Cellular fibronectin containing extra domain A (Fn-EDA), an endogenous ligand for toll-like-receptor 4 (TLR4), contributes to thrombo-inflammation. The role of Fn-EDA in the modulation of DVT is not elucidated yet.
OBJECTIVE
To determine whether Fn-EDA promotes DVT in the context of diet-induced obesity.
METHODS
Wild-type (WT) and Fn-EDA-deficient mice were either fed control or high-fat (HF) diet for 12 weeks. DVT was induced by inferior vena cava (IVC) stenosis and evaluated after 48 hours. Cellular Fn-EDA levels in the plasma of venous thromboembolism (VTE) patients were measured by sandwich ELISA.
RESULTS
We found that cellular Fn-EDA levels were significantly elevated in VTE patients' plasma and positively correlated with body mass index. HF diet-fed WT mice exhibited increased DVT susceptibility compared with control diet-fed WT mice. In contrast, HF diet-fed Fn-EDA-deficient mice exhibited significantly reduced thrombus weight and decreased incidence (%) of DVT compared with HF diet-fed WT mice concomitant with reduced neutrophil content and citrullinated histone H3-positive cells (a marker of NETosis) in IVC thrombus. Exogenous cellular Fn-EDA potentiated NETosis in neutrophils stimulated with thrombin-activated platelets via TLR4. Genetic deletion of TLR4 in Fn-EDA
CONCLUSION
These results demonstrate a previously unknown role of Fn-EDA in the DVT exacerbation, which may be an essential mechanism promoting DVT in the setting of diet-induced obesity.

Identifiants

pubmed: 33300307
doi: 10.1111/jth.15206
pmc: PMC8527852
mid: NIHMS1746125
pii: S1538-7836(22)00689-4
doi:

Substances chimiques

Fibronectins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

814-821

Subventions

Organisme : NIH HHS
ID : R01NS109910
Pays : United States
Organisme : NIH HHS
ID : U01NS113388
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL139926
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS113388
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118246
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118742
Pays : United States
Organisme : NIH HHS
ID : R35 HL139926
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS109910
Pays : United States

Informations de copyright

© 2020 International Society on Thrombosis and Haemostasis.

Références

J Lab Clin Med. 1989 May;113(5):586-97
pubmed: 2715681
Immunology. 1991 Sep;74(1):114-20
pubmed: 1937565
Obes Rev. 2002 May;3(2):85-101
pubmed: 12120424
Oncotarget. 2015 Aug 14;6(23):19350-1
pubmed: 26305982
Thromb Haemost. 2015 Jan;113(1):85-96
pubmed: 25318550
Thromb Res. 2008;122(4):549-55
pubmed: 18234295
Exp Mol Pathol. 1988 Jun;48(3):403-18
pubmed: 3371462
Acta Med Scand. 1987;222(3):275-9
pubmed: 3321923
Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):296-301
pubmed: 17991876
Inflammation. 2016 Jun;39(3):1059-68
pubmed: 27022744
PLoS One. 2012;7(7):e41254
pubmed: 22911769
Sci Transl Med. 2014 Apr 16;6(232):232ra50
pubmed: 24739758
Thromb Haemost. 2017 Jan 26;117(2):339-348
pubmed: 27975098
Thromb Haemost. 2018 Aug;118(8):1450-1460
pubmed: 29960272
Int Wound J. 2018 Aug;15(4):649-659
pubmed: 29536628
Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):147-51
pubmed: 23104849
Diabetes Care. 2001 Feb;24(2):323-7
pubmed: 11213886
Blood. 2015 May 14;125(20):3164-72
pubmed: 25700433
Stroke. 2019 May;50(5):1201-1209
pubmed: 30909835
PLoS One. 2013 May 31;8(5):e65061
pubmed: 23741455
Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):500-508
pubmed: 29326316
J Exp Med. 2012 Apr 9;209(4):819-35
pubmed: 22451716
J Cell Biol. 2003 Jul 7;162(1):149-60
pubmed: 12847088
Trends Immunol. 2018 Aug;39(8):610-623
pubmed: 29776849
Thromb Res. 2018 Oct;170:87-96
pubmed: 30138777
Open J Prev Med. 2012 Nov;2(4):499-509
pubmed: 26236563
J Clin Invest. 2014 Oct;124(10):4281-93
pubmed: 25180602
Circulation. 2015 Dec 8;132(23):2237-47
pubmed: 26508731
J Thromb Haemost. 2013 Jun;11 Suppl 1:233-41
pubmed: 23809127
J Vis Exp. 2017 Dec 22;(130):
pubmed: 29286428
Curr Opin Hematol. 2013 Sep;20(5):437-44
pubmed: 23817170
Am J Med. 2005 Sep;118(9):978-80
pubmed: 16164883
J Intern Med. 2015 May;277(5):573-84
pubmed: 25161014
Obes Res. 2003 Nov;11(11):1278-89
pubmed: 14627747
Methods Mol Biol. 2012;821:421-33
pubmed: 22125082
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1777-83
pubmed: 22652600
Circ Res. 2020 Jun 5;126(12):1779-1794
pubmed: 32195632
J Biol Chem. 2001 Mar 30;276(13):10229-33
pubmed: 11150311
J Vasc Surg. 2008 Dec;48(6):1575-84
pubmed: 18829216

Auteurs

Nirav Dhanesha (N)

Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.

Manish Jain (M)

Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.

Prakash Doddapattar (P)

Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.

Anetta Undas (A)

Institute of Cardiology, Jagiellonian University, Kraków, Poland.

Anil K Chauhan (AK)

Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH